- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- ALEMBIC PHARMACEUTICALS LTD. (pharmaceuticals)
- Latest 8 Quarter Result
ALEMBIC PHARMA Quarterly Results 
(APLL)
Here are the latest quarterly results of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA financial fact sheet and ALEMBIC PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
ALEMBIC PHARMA Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-17* |
3
Jun-17* |
3
Sep-17* |
3
Dec-17* |
3
Mar-18* |
3
Jun-18* |
3
Sep-18* |
3
Dec-18* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 7,414 | 6,482 | 7,893 | 8,400 | 8,533 | 8,625 | 11,271 | 10,182 | |
| Other income | Rs m | 9 | 2 | 77 | 3 | 6 | 1 | 24 | 35 | |
| Turnover | Rs m | 7,422 | 6,484 | 7,970 | 8,404 | 8,540 | 8,626 | 11,294 | 10,217 | |
| Expenses | Rs m | 6,086 | 5,468 | 6,101 | 6,525 | 6,801 | 7,115 | 8,247 | 7,759 | |
| Gross profit | Rs m | 1,347 | 1,014 | 1,791 | 1,875 | 1,730 | 1,510 | 3,023 | 2,422 | |
| Depreciation | Rs m | 218 | 218 | 257 | 264 | 316 | 276 | 286 | 291 | |
| Interest | Rs m | 18 | 9 | 4 | 8 | 13 | 16 | 58 | 60 | |
| Profit before tax | Rs m | 1,119 | 789 | 1,608 | 1,606 | 1,408 | 1,220 | 2,703 | 2,108 | |
| Tax | Rs m | 165 | 155 | 366 | 298 | 385 | 315 | 703 | 400 | |
| Profit after tax | Rs m | 954 | 634 | 1,242 | 1,309 | 1,022 | 904 | 2,000 | 1,708 | |
| Gross profit margin | % | 18.2 | 15.6 | 22.7 | 22.3 | 20.3 | 17.5 | 26.8 | 23.8 | |
| Effective tax rate | % | 14.7 | 19.6 | 22.7 | 18.5 | 27.4 | 25.9 | 26.0 | 19.0 | |
| Net profit margin | % | 12.9 | 9.8 | 15.7 | 15.6 | 12.0 | 10.5 | 17.7 | 16.8 | |
| Diluted EPS | Rs | 5.1 | 3.4 | 6.6 | 6.9 | 5.4 | 4.8 | 10.6 | 9.1 | |
| Diluted EPS (TTM) | Rs | 21.5 | 19.4 | 19.6 | 22.0 | 22.3 | 23.8 | 27.8 | 29.9 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: ALEMBIC PHARMA 2QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: DIVIS LABORATORIES BIOCON LTD VENUS REMEDIES FULFORD INDIA CADILA HEALTHCARE
Compare ALEMBIC PHARMA With: DIVIS LABORATORIES BIOCON LTD VENUS REMEDIES FULFORD INDIA CADILA HEALTHCARE
Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Recapitalisation Package for PSBs: The Pros & Cons(Podcast)
Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.
Views on news
ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 21, 2018 | Updated on Dec 21, 2018Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.
ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)
Oct 23, 2018 | Updated on Oct 23, 2018For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)
Jul 30, 2018 | Updated on Jul 30, 2018For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)
Feb 13, 2019The real estate sector is ready to make a comeback. This is the stock to consider buying.
Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)
Feb 14, 2019During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)
Feb 14, 2019Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)
Feb 12, 2019Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.
The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)
Feb 15, 2019Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.
More|
| |
ALEMBIC PHARMA SHARE PRICE
Feb 22, 2019 (Close)
TRACK ALEMBIC PHARMA
- Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ALEMBIC PHARMA
ALEMBIC PHARMA - MYLAN COMPARISON
COMPARE ALEMBIC PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.